Australian biotech Cartherics partners with UQ and USyd on a $4.9M MRFF-funded project to develop iPSC-derived cardiomyocytes for heart tissue regeneration.
Australian biotech firm Cartherics partners with The University of Queensland and The University of Sydney on a $4.9M MRFF-funded project, developing iPSC-derived cardiomyocytes (iPSC-CMs) to regenerate damaged heart tissue and enhance heart function. The universities grant Cartherics exclusive rights to their iPSC line for cardiovascular diseases, with Cartherics gaining access to tech developed by the universities in other fields.
July 25, 2024
4 Articles